FORWARD Sample Clauses

FORWARD. The Statements of Policy contained in this booklet have been re-worded for the sake of brevity and clarity, and have been agreed to by both labour and management representatives. They are intended as a supplemental guide in the interpretation of the Agreement on the points which they cover. Whereas the Joint Labor Agreement is referred to in the following statements of Policy, it is agreed upon that the Labor Agreement is the successor to the old Joint Labor Agreement. STATEMENTS OF POLICY
FORWARD. Except as stated or as modified hereinafter, the conditions and provisions of the Pile DriversStandard Agreement apply. It is agreed that when diving conditions change, the Divers’ Agreement will be re-opened for negotiations at a time mutually agreed on by both parties of this agreement. It is also understood and agreed that violations of this agreement by diving firms signatory to the Divers’ Agreement regarding wage rates and other benefits as provided in Clause 1 may result, pursuant to the grievance procedure, in the offending party being subject to an audit by the union’s auditor and/or the posting of a cash bond which will be held by the union in accordance with Clause 6.08 of the Pile Drivers’ Standard Agreement. CLAUSE 1 – WAGES HOURLY WAGE RATES APRIL 28, 2019 THROUGH APRIL 30, 2022 April 28/19 May 3/20 May 2/21 Diving Supervisor $77.99 $79.32 $80.68 Diver $70.90 $72.11 $73.33 Standby Diver $52.10 $53.09 $54.09 ROV Operator $52.10 $53.09 $54.09 Tender $41.42 $42.27 $43.12 Vacation and statutory holiday pay consisting of six percent (6%) of gross earnings for annual vacations and six percent (6%) of gross earnings for statutory holiday pay shall be paid to the employee on every regular payday. Tender’s Rate to be the Pile Driver/Bridgeworker Rate BF = Bridgeworker Foreman Rate Diving Supervisor 165% BF Rate ** Diver 150% BF ** Standby Diver 110% BF ** ROV Operator 110% BF ** Tender Pile Driver/Bridgeworker Rate * * Add fifty-four cents (54¢) per hour to the Tender rate for Welder premium ** Wage percentage formulas suspended for the 2019 – 2022 agreement
FORWARD. The purpose of this working document is to provide updated Information to the Board and the Association and teachers and Administrators in implementing and working with the provisions of the melded 2013 - 2019 Collective Agreement. These provisions include the previous 2011 – 2013 Collective Agreement, the previous 2006 - 2011 Collective Agreement, the 2001 – 2004 Provincial Collective Agreement, the previous 1998 – 2001 RSD - RTA Collective Agreement, legislative changes and the 2013-2019 Provincial Agreement. This working document is organized to facilitate ready access to information. It is not the official collective agreement and therefore, if there are errors or omissions or disagreement as to sequencing and format, the original documents as agreed to by BCPSEA and BCTF and/or as legislated shall prevail. Provincial Matters Articles and Clauses are found first in each Section. Local matters Articles and Clauses generally follow the provincial language.
FORWARD. This Agreement resulting from Collective Bargaining between The Leamington United Mennonite Home & Apartments, a faith centered, church supported charitable eldercare provider owned by area Mennonite Churches and Unifor and its Local 2458 is for the purpose of producing the most favourable relationship between the employees and the employer. The strongest effort should be exerted by everyone concerned to make it an effective document for the benefit of all. We strongly urge all union employees to consult with their Committeepersons or Union Representatives concerning any matter pertaining to the provisions of the Agreement.
FORWARD. Forward may immediately terminate this Agreement in writing in the event that development and Commercialization of the Patent Rights, Fumaric Acid Products and Fumaric Acid Processes in the reasonable opinion of Forward are no longer commercially feasible.
FORWARD. LOOKING STATEMENT - ASTERIAS Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Asterias, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the businesses of Asterias, particularly those mentioned in the cautionary statements found in Asterias’s filings with the Securities and Exchange Commission. Asterias disclaims any intent or obligation to update these forward-looking statements. FORWARD-LOOKING STATEMENT - BIOTIME Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products or diagnostic tests, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the m...